Member Info for T0n1c

Contender, I'm the same and filter nobody.. but these last couple of days has really drawn out some newer, not so (far from) interesting, posters.
This place has turned worse than SYME, and I never thought that possible.

My only advise to any new investors around here is take all views into consideration, and make your own decisions, but definitely look a posters posting history to get a sense of what their angle may be.
There are a fair few, self confessed admittedly, others not so much, day traders who will do their best to knock the share, buy in and become the biggest fan... rinse repeat.

GLA

@the_realist
In this article;
https://www.heraldscotland.com/news/19162128.scots-firm-omega-scoops-375m-contract-government-produce-instant-covid-tests/
Omega said production of Covid-19 tests would only begin once the government had provided confirmation that MOLOGIC’s test “has passed the necessary performance evaluation.”
It's all to play for.

crossed over with MerchantBankers post.. soz

Is it not 200m shared between Omega and GAD?

If so, 100m is Omegas max'ed out capacity, on current plans, for a year, but we've also been informed by Walbrook that we will have capacity for other LFT production.

So I'm therefore assuming £374 = 100m tests = £3.74 a test @50% margin (assumed, based on previous expectation of
the Mologic AG test shared on November investor presentation) = £1.87 profit per test.

All to be confirmed though... so pure speculation at this time.

https://www.heraldscotland.com/news/19162128.scots-firm-omega-scoops-375m-contract-government-produce-instant-covid-tests/

Seems we're waiting on the government.

Omega said production of Covid-19 tests would only begin once the government had provided confirmation that Mologic’s test “has passed the necessary performance evaluation.”

For those that have been around long enough....
It's nothing compared to the post Sky news speeding ticket drop
It's nothing on the mid investor presentation MM (?) drop
It's a drop in the ocean compared to the vaccine news drop

Yes the RNS wasn't the best worded but I do think Colin, based on some of the above history, was trying to protect people from being spiked.
This contract news wasn't, despite what some think, the ONE. It's a great apetiser, and one I'd hoped would have at least held us just above 100 but it's doesn't give us, what test has been selected? production numbers? costs/ margin? what capacity does it leave us for other production runs?
We shall just have to wait a little longer for that information.

If you've been around, invested, and witnessed the above drops, then you will most likely be in profit.
If you've invested since the above times, then I think Colins (overly) cautious tone in todays RNS has probably either saved you some money, or not got you locked in at a higher price point.

-5.58% is not the hardest knock on the chin we've had.. neither, I suspect, will it be the last.

Those are my views... feel free to add whatever cr8p you want to them... if there's any more, after today, to be added on this board.

@SneakySimon
You're right, I should have said government backed (in that the RTC was formed, and somewhat funded, by the UK Gov). My opinion is that the previous arrangement/framework was binned in response to the GLP action taken against the Gov. IMO, with the dynamic purchasing strategy now in place we'll see orders for ABC-19 in due course.

On the DHSC selected test front.. there's too many unknowns on this one, I think.
I think the network of UK diagnostics companies has been pulled together, spearheaded (scarily) by DHSC, to get them all talking/working together to expedite the best test(s) as quickly as possible. This, in addition to the UK vaccine programme, could be a great win for the UK Gov in creating the next generation Lateral Flow Tests (easier to use, improved efficacy).

Mologic are the constant across all that we are aware of.
They have their own test CE marked test.
They partnered with Vatic on the saliva based test (currently trialled in Edinburgh airport)
They are patterned with Avacta.
ODX are well connected with Mologic.

Some thoughts.. and just throwing them out there:
CE marked Mologic test - great.. we must be done on that TT by now.
Mologic/Vatic - great.. we work well with Mologic
Mologic/Avacta - great.. we work well with Mologic, and there was the Omega/Avacta link some months back from the LinkedIn profile of the Omega employee (Adrian).
It could very well be that Omega have TT underway/near completion for all 3 of the above, in readiness for any decision made.
As I say, I'm just spitballing.

DYOR

So now the dust has settled, somewhat… what do we have?

First of all we have a CEO who looks to protect investors, by setting out very clearly that there is more news to come and that numbers will become clearer in time.
I for one, am grateful for that, if only for the reason of avoiding whinging ‘gamblers’ forever complaining that they got spiked until such time they can get out.

Secondly.. It seems some here have overlooked the FACT that we just had confirmation (again) that we’re a UK Gov validated/approved/CONTRACTED manufacturer, for a second Covid test (in addition to the ABC-19 test). We will see a steady increase from here on in. Not in a straight line.. but the trend is up.
Sit back, relax.

It doesn’t matter that test(s) the DHSC select. Omega are contracted to produce them.
Colin has responded to a Q&A, “We are happy with the terms of the contract and that we will receive a fair price for the work we undertake for the Government”.
Sit back, relax.

So to re-cap, Omega are, but not limited to:
UK Gov approved to manufacture ABC-19 - Covid Antibody rapid test
UK Gov approved to manufacture DHSC selected - Covid Antigen rapid test(s)
WHO approved to supply - CD4 HIV tests
China approved to supply - Self test Food intolerance tests

30 countries are currently evaluating the ABC-19 test alone.
No doubt once a DHSC AG test is available, that will be appealing to other countries also.
Sit back, relax.

GLA

FSA? Really? What exactly has been shared that would be of interest to them?

https://www.find-tender.service.gov.uk/Notice/005133-2021?origin=SearchResults&p=1

I can't take credit for the explanation. That was all down to Jarv55.
I've certainly saved it and happy to share though.
GLA

Courtesy of Jarv55, which I think gives a good summary:

For those that still don’t fully understand the Syme model. It is about providing immediate working capital to companies. It is a very simple model where Syme are the middle man between the borrower and the funder.
Syme employs risk assessors who have a strict criteria when performing due diligence on the company. They do not take on companies with a bad credit history. Syme receives an upfront fee of 2% (non-returnable) if the company passes the due diligence process the funder then lends money to the company based on the valuation of their stock.
The funder then owns the inventory, this is known as a true sale, but the company keeps the stock in their warehouse and can still sell the stock. The company has to pay back the funder over a 3 year period this includes a rolling 3 year interest. Syme also takes an annual 2% net fee (3% if done through the captive Bank) costs are small to Syme.
The money that the company is lent does not show as debt on the balance sheet as it’s not a loan because the funder has actually purchased the inventory, if this was done through a bank, it would show as debt on the balance sheet, as the money is borrowed based on assets, the bank would never own them (unlike the Syme model).
The funders loan actually strengthens the company balance sheet. And gives them more liquidity. This in turn would give them a better credit rating.

All inventory that is funded is recorded and monetised on the blockchain through SIA a payment services tech firm which uses a fintech platform to optimise the firms working capital. SIA monetise the assets by tracking their movement and always make sure assets are there for the funder as collateral.
The company can repay the funder in full before the 3yr contract is up, or it can roll it over past the 3yr term dependant on further due diligence. Company X gets funds upfront for working capital based on its inventory, which it can in turn sell even though the funder owns them.
As long as company X keeps payments up and repays borrowed funds within the 3 year time frame, it works for everyone. The Funders get a good return on lending their money for a 3 year period.
The unique benefit of the Syme model is there is no risk for Syme. If for any reason Company X goes bankrupt, Syme has already been paid upfront and are not liable for any losses the funder has received X amount plus still owns the inventory which can be sold.
With the model being Sharia law compliant this opens up another untapped market. The Syme model is an international scalable market place for all.

Stu, the reason I choose to read, and appreciate, Big Jocks comments is because they are factual, support previous released news, are interesting opinions..... yours on the other hand, hmmmm, not so much.

Choose to trust who you like. Really, nobody is forcing you to.
I find It very odd that you repeatedly, in your 18 posts or so, try and slander other posters on the board.
Maybe have a beer and chill out.

Much of what Big Jock posts is fact based, highlighting what is already know in RNS.
He also goes the extra mile in acting as a liaison to Colin.
It's up to anyone on this board to trust in what Big Jock posts... or don't. Your call.
As Tecbadger points out, you should always DYOR.

@Big Jock, thanks for the work you put in for many on the board.

There is an odd pattern of multiple £10.01k buys going through this morning.
Doesn't mean a single buyer of course.

I think he's over on twitter, making friends, these days.

Thanks for interpreting... I was struggling to understand the tweet :-)

https://twitter.com/ShareTalkNews/status/1369385331624181772

Feels as though there is a whole heap of 'stuff' just bubbling up ready to explode.

Lateral flow device specificity in phase 4 (post marketing) surveillance
"These analyses support the policy of not requiring PCR confirmation of positive LFD tests conducted at ATSs under current levels of population prevalence."
Evidence to support the UK Gov spending £8bn on LFT testing, thank you.... What chunk of that are we going to see?
https://twitter.com/Abingdon_Health/status/1369616725138944001
"Greece would accept tourists without quarantine or restrictions if they could prove...they had #antibodies" -

https://www.lse.co.uk/rns/ABDX/interim-results-p8a2k5nepdi13hm.html
"The Company is making good progress in the approval of AbC-19™ for testing in the US as well as with over 30 other countries worldwide."
"In the current financial year, the key driver of the Company's financial performance will be the predicted roll-out of antibody testing in the territories that Abingdon Health is targeting and the sales of its AbC-19™ COVID-19 rapid test. Abingdon Health has a growing pipeline of international opportunities, with seven countries now identified as Tier 1 commercial targets which have potential to deliver significant order volume in this financial year"
*Financial year end is 30th June
It certainly feels like there's stuff going on in the background with the ABC-19 test.

Another ABC-19 sales channel:
https://www.investegate.co.uk/abingdon-health-plc--abdx-/gnw/abingdon-health-plc-signs-distribution-agreement-with-biosure-uk/20210310091027H1440/

And I'm sure there's a whole heap more...

@sharebel
The RNS states:
"SYME also confirms that it will be issuing a Trading Update to the market before the end of this month."

BEFORE the end of the month.. not at the end of the month. Anytime between now and the end of the month.